HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Israel, O. Articles by Kuten, A. Search for Related Content PubMed PubMed Citation Articles by Israel, O. Articles by Kuten, A.

Early Detection of Cancer Recurrence: ¹⁸F-FDG PET/CT Can Make a Difference in Diagnosis and Patient Care

¹ Department of Nuclear Medicine, Rambam Health Care Campus, Haifa, Israel; ² B. Rappaport School of Medicine, Technion–Israel Institute of Technology, Haifa, Israel; and ³ Department of Oncology, Rambam Health Care Campus, Haifa, Israel

Correspondence: For correspondence or reprints contact: Ora Israel, MD, Department of Nuclear Medicine, Rambam Health Care Campus, Haifa 35254, Israel. E-mail: o_israel{at}rambam.health.gov.il

Early detection of recurrence is clinically important and can improve the prognosis and survival of patients with cancer. CT, considered the primary method of investigation because of its low cost and widespread availability, provides high-resolution anatomic details but may underestimate the actual tumor burden by overlooking small tumor clusters in areas of distorted anatomy after treatment. ¹⁸F-FDG PET is an effective whole-body imaging technique that detects metabolic changes preceding structural findings. However, the specificity of PET is impaired by false-positive or equivocal results attributable to the lack of precise anatomic landmarks and to sites of increased ¹⁸F-FDG uptake of nonmalignant etiology. PET/CT provides fused images that demonstrate the complementary roles of functional and anatomic assessments in the diagnosis of cancer recurrence through the precise localization of suspected ¹⁸F-FDG foci and their characterization as malignant or benign. In addition to the accurate diagnosis and definition of the whole extent of recurrent cancer, PET/CT has an impact on patient management because it can assist in defining potential candidates for surgery for cure, planning the appropriate surgical or radiotherapy approach, and referring patients with unresectable disease to other therapeutic options.

Key Words: cancer • recurrence • ¹⁸F-FDG • PET/CT

COPYRIGHT © 2006 by the Society of Nuclear Medicine, Inc.

This article has been cited by other articles:

				A. A. Onitilo, J. M. Engel, J. M. Demos, and B. Mukesh Prognostic Significance of (18) F-Fluorodeoxyglucose - Positron Emission Tomography After Treatment in Patients With Limited Stage Small Cell Lung Cancer Clin. Med. Res., September 1, 2008; 6(2): 72 - 77. [Abstract] [Full Text] [PDF]

				J. E Burdette In vivo imaging of molecular targets and their function in endocrinology J. Mol. Endocrinol., June 1, 2008; 40(6): 253 - 261. [Abstract] [Full Text] [PDF]

				D. W. Townsend Dual-Modality Imaging: Combining Anatomy and Function J. Nucl. Med., June 1, 2008; 49(6): 938 - 955. [Abstract] [Full Text] [PDF]

				J. Czernin and H. R. Schelbert Introduction J. Nucl. Med., January 1, 2007; 48(1_suppl): 2S - 3S. [Full Text] [PDF]